OriGene Technologies, Inc. announced today the acquisition of Beijing Zhongshan Golden Bridge Biotechnology Co., Ltd (ZsBio).
Founded in the year 1993, ZsBio provides testing products (pathology) within their domestic Chinese market, such as oncology diagnostics.
OriGene had the following to say regarding today’s acquisition, “With its leadership position in the Chinese pathology testing market, ZsBio is the ideal partner for OriGene,” said Wei-Wu He, CEO of OriGene. “ZsBio is already a leader in pathology products for cancer applications and has a wide range of market-leading diagnostics products used in hospitals and laboratories in China. In turn, OriGene brings to ZsBio innovative highly specific monoclonal antibodies and assays to complement and strengthen ZsBio’s portfolio of products.”
In a market that has experienced double-digit market growth annually, OriGene hopes the acquisition of ZsBio bolsters their bottom-line.
OriGene Technologies, Inc., is a biosciences company dedicated to develop gene centric innovative products and services to improve the quality of healthcare diagnostics and treatments while ZsBio has more than 25 years of pathology diagnostics experience in China.
